East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Deferasirox Oral Granules, 90 mg,180 mg, and 360 mg. Aurobindo Pharma’s Deferasirox Oral Granules, are an AB-rated generic equivalent to the reference listed drug (RLD), Jadenu Sprinkle Granules manufactured by Novartis Pharmaceuticals Corporation

Deferasirox Oral Granules are indicated for the treatment of:

• Chronic iron overload due to blood transfusions (transfusional iron overload).
• Chronic iron overload in non-transfusion-dependent thalassemia syndromes.